470 related articles for article (PubMed ID: 21997392)
1. APOL1 localization in normal kidney and nondiabetic kidney disease.
Madhavan SM; O'Toole JF; Konieczkowski M; Ganesan S; Bruggeman LA; Sedor JR
J Am Soc Nephrol; 2011 Nov; 22(11):2119-28. PubMed ID: 21997392
[TBL] [Abstract][Full Text] [Related]
2. APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy.
Kopp JB; Nelson GW; Sampath K; Johnson RC; Genovese G; An P; Friedman D; Briggs W; Dart R; Korbet S; Mokrzycki MH; Kimmel PL; Limou S; Ahuja TS; Berns JS; Fryc J; Simon EE; Smith MC; Trachtman H; Michel DM; Schelling JR; Vlahov D; Pollak M; Winkler CA
J Am Soc Nephrol; 2011 Nov; 22(11):2129-37. PubMed ID: 21997394
[TBL] [Abstract][Full Text] [Related]
3. Apolipoprotein l1 and the genetic basis for racial disparity in chronic kidney disease.
Quaggin SE; George AL
J Am Soc Nephrol; 2011 Nov; 22(11):1955-8. PubMed ID: 21997393
[No Abstract] [Full Text] [Related]
4. APOL1 variants increase risk for FSGS and HIVAN but not IgA nephropathy.
Papeta N; Kiryluk K; Patel A; Sterken R; Kacak N; Snyder HJ; Imus PH; Mhatre AN; Lawani AK; Julian BA; Wyatt RJ; Novak J; Wyatt CM; Ross MJ; Winston JA; Klotman ME; Cohen DJ; Appel GB; D'Agati VD; Klotman PE; Gharavi AG
J Am Soc Nephrol; 2011 Nov; 22(11):1991-6. PubMed ID: 21997397
[TBL] [Abstract][Full Text] [Related]
5. Sequencing rare and common APOL1 coding variants to determine kidney disease risk.
Limou S; Nelson GW; Lecordier L; An P; O'hUigin CS; David VA; Binns-Roemer EA; Guiblet WM; Oleksyk TK; Pays E; Kopp JB; Winkler CA
Kidney Int; 2015 Oct; 88(4):754-63. PubMed ID: 25993319
[TBL] [Abstract][Full Text] [Related]
6. Association of APOL1 Genotype with Renal Histology among Black HIV-Positive Patients Undergoing Kidney Biopsy.
Atta MG; Estrella MM; Skorecki KL; Kopp JB; Winkler CA; Wasser WG; Shemer R; Racusen LC; Kuperman M; Foy MC; Lucas GM; Fine DM
Clin J Am Soc Nephrol; 2016 Feb; 11(2):262-70. PubMed ID: 26668025
[TBL] [Abstract][Full Text] [Related]
7. Absence of APOL1 risk variants protects against HIV-associated nephropathy in the Ethiopian population.
Behar DM; Kedem E; Rosset S; Haileselassie Y; Tzur S; Kra-Oz Z; Wasser WG; Shenhar Y; Shahar E; Hassoun G; Maor C; Wolday D; Pollack S; Skorecki K
Am J Nephrol; 2011; 34(5):452-9. PubMed ID: 21968148
[TBL] [Abstract][Full Text] [Related]
8. APOL1 and kidney disease.
Pollak MR; Genovese G; Friedman DJ
Curr Opin Nephrol Hypertens; 2012 Mar; 21(2):179-82. PubMed ID: 22257798
[TBL] [Abstract][Full Text] [Related]
9. High risk APOL1 genotypes and kidney disease among treatment naïve HIV patients at Kano, Nigeria.
Abdu A; Duarte R; Dickens C; Dix-Peek T; Bala SM; Ademola B; Naicker S
PLoS One; 2022; 17(10):e0275949. PubMed ID: 36227935
[TBL] [Abstract][Full Text] [Related]
10. APOL1-G0 protects podocytes in a mouse model of HIV-associated nephropathy.
Bruggeman LA; Wu Z; Luo L; Madhavan S; Drawz PE; Thomas DB; Barisoni L; O'Toole JF; Sedor JR
PLoS One; 2019; 14(10):e0224408. PubMed ID: 31661509
[TBL] [Abstract][Full Text] [Related]
11. HIV-associated nephropathy: pathogenesis.
Medapalli RK; He JC; Klotman PE
Curr Opin Nephrol Hypertens; 2011 May; 20(3):306-11. PubMed ID: 21358326
[TBL] [Abstract][Full Text] [Related]
12. APOL1 risk variants predict histopathology and progression to ESRD in HIV-related kidney disease.
Fine DM; Wasser WG; Estrella MM; Atta MG; Kuperman M; Shemer R; Rajasekaran A; Tzur S; Racusen LC; Skorecki K
J Am Soc Nephrol; 2012 Feb; 23(2):343-50. PubMed ID: 22135313
[TBL] [Abstract][Full Text] [Related]
13. Localization of APOL1 protein and mRNA in the human kidney: nondiseased tissue, primary cells, and immortalized cell lines.
Ma L; Shelness GS; Snipes JA; Murea M; Antinozzi PA; Cheng D; Saleem MA; Satchell SC; Banas B; Mathieson PW; Kretzler M; Hemal AK; Rudel LL; Petrovic S; Weckerle A; Pollak MR; Ross MD; Parks JS; Freedman BI
J Am Soc Nephrol; 2015 Feb; 26(2):339-48. PubMed ID: 25012173
[TBL] [Abstract][Full Text] [Related]
14. APOL1 risk variants enhance podocyte necrosis through compromising lysosomal membrane permeability.
Lan X; Jhaveri A; Cheng K; Wen H; Saleem MA; Mathieson PW; Mikulak J; Aviram S; Malhotra A; Skorecki K; Singhal PC
Am J Physiol Renal Physiol; 2014 Aug; 307(3):F326-36. PubMed ID: 24899058
[TBL] [Abstract][Full Text] [Related]
15. APOL1 variants in HIV-associated nephropathy: just one piece of the puzzle.
Hays T; Wyatt CM
Kidney Int; 2012 Aug; 82(3):259-60. PubMed ID: 22791322
[TBL] [Abstract][Full Text] [Related]
16. APOL1 risk variants and the development of HIV-associated nephropathy.
Goyal R; Singhal PC
FEBS J; 2021 Oct; 288(19):5586-5597. PubMed ID: 33340240
[TBL] [Abstract][Full Text] [Related]
17. Impact of APOL1 polymorphism and IL-1β priming in the entry and persistence of HIV-1 in human podocytes.
Mikulak J; Oriolo F; Portale F; Tentorio P; Lan X; Saleem MA; Skorecki K; Singhal PC; Mavilio D
Retrovirology; 2016 Sep; 13(1):63. PubMed ID: 27599995
[TBL] [Abstract][Full Text] [Related]
18. HIV-associated nephropathy patients with and without apolipoprotein L1 gene variants have similar clinical and pathological characteristics.
Atta MG; Estrella MM; Kuperman M; Foy MC; Fine DM; Racusen LC; Lucas GM; Nelson GW; Warner AC; Winkler CA; Kopp JB
Kidney Int; 2012 Aug; 82(3):338-43. PubMed ID: 22495294
[TBL] [Abstract][Full Text] [Related]
19. Clinical phenotype of APOL1 nephropathy in young relatives of patients with end-stage renal disease.
Anyaegbu EI; Shaw AS; Hruska KA; Jain S
Pediatr Nephrol; 2015 Jun; 30(6):983-9. PubMed ID: 25530085
[TBL] [Abstract][Full Text] [Related]
20. Clinical Features and Histology of Apolipoprotein L1-Associated Nephropathy in the FSGS Clinical Trial.
Kopp JB; Winkler CA; Zhao X; Radeva MK; Gassman JJ; D'Agati VD; Nast CC; Wei C; Reiser J; Guay-Woodford LM; Pollak MR; Hildebrandt F; Moxey-Mims M; Gipson DS; Trachtman H; Friedman AL; Kaskel FJ;
J Am Soc Nephrol; 2015 Jun; 26(6):1443-8. PubMed ID: 25573908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
